|
Market Closed -
Oslo Bors
18:45:00 28/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 13.40 NOK | +2.68% |
|
+4.28% | -43.70% |
| 10-20 | Navamedic Extends Nordic Rights for Mysimba Obesity Drug | MT |
| 10-20 | Navamedic ASA Extends Mysimba Distribution Agreement With Azurity Pharmaceuticals | CI |
Company Valuation: Navamedic ASA
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 555.8 | 601.2 | 636.8 | 453.9 | 570.8 | 321.4 | - | - |
| Change | - | 8.19% | 5.92% | -28.72% | 25.74% | -43.7% | - | - |
| Enterprise Value (EV) 1 | 542.1 | 597.9 | 745.4 | 453.9 | 702.3 | 439.1 | 417.1 | 378.6 |
| Change | - | 10.3% | 24.65% | -39.1% | 54.71% | -37.48% | -5% | -9.24% |
| P/E | 850x | 20.2x | 195x | - | -19.3x | -38.7x | 29.1x | 14.7x |
| PBR | - | 2.87x | 2.86x | 2.1x | - | 1.05x | 1.02x | 0.95x |
| PEG | - | 0x | -2.2x | - | - | 0.5x | -0x | 0.1x |
| Capitalization / Revenue | 2x | 1.57x | 1.24x | 0.85x | 1.01x | 0.57x | 0.54x | 0.5x |
| EV / Revenue | 1.95x | 1.56x | 1.46x | 0.85x | 1.24x | 0.78x | 0.7x | 0.59x |
| EV / EBITDA | 29.8x | 11.6x | 14.5x | 9.75x | 14.8x | 7.72x | 6.54x | 4.83x |
| EV / EBIT | 47.3x | 13.5x | 18.8x | 18.8x | 56.6x | 48.8x | 16.2x | 9.1x |
| EV / FCF | -267x | 38.1x | -7.28x | 12.8x | -4.36x | 12.4x | 11.4x | 7.51x |
| FCF Yield | -0.37% | 2.62% | -13.7% | 7.84% | -22.9% | 8.06% | 8.74% | 13.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.04 | 1.73 | 0.188 | - | -1.236 | -0.3467 | 0.46 | 0.9133 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 278.4 | 382.1 | 512 | 531.4 | 565.4 | 566.4 | 598 | 640.7 |
| EBITDA 1 | 18.2 | 51.69 | 51.57 | 46.55 | 47.61 | 56.9 | 63.77 | 78.33 |
| EBIT 1 | 11.46 | 44.44 | 39.64 | 24.13 | 12.4 | 9 | 25.7 | 41.6 |
| Net income 1 | 0.618 | 29.43 | 3.814 | 1.29 | -23.54 | -8.5 | 11.5 | 21.83 |
| Net Debt 1 | -13.64 | -3.304 | 108.5 | - | 131.5 | 117.7 | 95.77 | 57.23 |
| Reference price 2 | 34.00 | 34.90 | 36.70 | 25.70 | 23.80 | 13.40 | 13.40 | 13.40 |
| Nbr of stocks (in thousands) | 16,346 | 17,228 | 17,353 | 17,663 | 23,981 | 23,981 | - | - |
| Announcement Date | 2/17/22 A | 2/16/23 A | 2/15/24 A | 2/12/25 A | 2/12/26 A | - | - | - |
1NOK in Million2NOK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -37.64x | 0.76x | 7.57x | - | 33.55M | |
| 37.66x | 13.18x | 27.98x | 0.53% | 1,143B | |
| 39.33x | 6.61x | 18.6x | 1.99% | 647B | |
| 37.45x | 8.4x | 17.37x | 2.4% | 506B | |
| 21.46x | 5.22x | 12.98x | 2.51% | 384B | |
| 103.38x | 5.8x | 24.86x | 2.4% | 350B | |
| 21.99x | 5.69x | 13.69x | 2.94% | 293B | |
| 22.31x | 4.51x | 12.87x | 1.96% | 265B | |
| 28.42x | 7.28x | 13.03x | 2.25% | 242B | |
| -45.78x | 7.1x | 27.53x | 2.07% | 197B | |
| Average | 22.86x | 6.45x | 17.65x | 2.12% | 402.76B | |
| Weighted average by Cap. | 35.27x | 8.35x | 20.48x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- NAVA Stock
- Valuation Navamedic ASA
Select your edition
All financial news and data tailored to specific country editions
